Vipivotide tetraxetan Linker
Code | Size | Price |
---|
TAR-T17233-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T17233-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Vipivotide tetraxetan Linker (PSMA-617 Linker) is a nonclaevable peptide linker for synthesis of Vipivotide tetraxetan (PSMA-617). Vipivotide tetraxetan (PSMA-617) is a ligand used to synthesize 177Lu-PSMA-617, which is a radioactive molecule for the treatment of prostate cancer[1].
CAS:
1703768-74-4
Molecular Weight:
655.74
Purity:
0.98
SMILES:
C([C@H](NC(=O)[C@@H]1CC[C@@H](CN)CC1)C(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)=O)C2=CC3=C(C=C2)C=CC=C3
References
Bene?ov? M, et al. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018 Mar 5;15(3):934-946.